Lexington Biosciences, Inc. is a medical device company, which engages in the research and development of non-diagnostic devices. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-06-01. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The firm is in the final stages of releasing the developed product for clinical studies. The firm's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
How did LXGTF's recent EPS compare to expectations?
The most recent EPS for Lexington Biosciences Holdings Corp is $, expectations of $.
How did Lexington Biosciences Holdings Corp LXGTF's revenue perform in the last quarter?
Lexington Biosciences Holdings Corp revenue for the last quarter is $
What is the revenue estimate for Lexington Biosciences Holdings Corp?
According to of Wall street analyst, the revenue estimate of Lexington Biosciences Holdings Corp range from $ to $
What's the earning quality score for Lexington Biosciences Holdings Corp?
Lexington Biosciences Holdings Corp has a earning quality score of B+/51.58307. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Lexington Biosciences Holdings Corp report earnings?
Lexington Biosciences Holdings Corp next earnings report is expected in
What are Lexington Biosciences Holdings Corp's expected earnings?
Lexington Biosciences Holdings Corp expected earnings is $, according to wall-street analysts.
Did Lexington Biosciences Holdings Corp beat earnings expectations?
Lexington Biosciences Holdings Corp recent earnings of $ expectations.